The 2022 Tandem Meetings | Haploidentical vs MUD transplantation in patients with lymphoma using PTCy

Alberto Mussetti, MD, The Catalan Institute of Oncology, Barcelona, Spain, comments on the findings of a retrospective study comparing the outcomes of patients with lymphoma who have received haploidentical vs matched unrelated donor (MUD) transplantation with post-transplant cyclophosphamide (PTCy). Overall, the study reported that patients who received a MUD transplant had a significantly better overall survival (OS), progression-free survival (PFS), as well as a better non-relapse mortality (NRM), and a lower incidence of acute and chronic graft-versus-host disease (GvHD). However, there were no differences in the relapse rate between the two cohorts. A sensitivity analysis was performed to address any bias caused by differences between the two study cohorts. Nevertheless, results should still be validated in a randomized prospective study. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.